Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) Stock Competitors & Peer Comparison
See ZENITHDRUG.NS's competitors and their performance on the NSE and across the wider stock market.
Peer Comparison Table: Medical - Pharmaceuticals Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ZENITHDRUG.NS and its NSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ZENITHDRUG.NS | ₹39.80 | -1.97% | 668.8M | 16.96 | ₹2.30 | N/A |
| ABBOTINDIA.NS | ₹25,725.00 | -1.70% | 550.5B | 34.98 | ₹740.50 | +2.53% |
| ABBOTINDIA.BO | ₹25,698.00 | -1.75% | 550.5B | 34.89 | ₹740.55 | +2.53% |
| JBCHEPHARM.NS | ₹2,416.10 | +0.30% | 387.9B | 52.07 | ₹46.40 | +0.91% |
| JBCHEPHARM.BO | ₹2,412.25 | -3.70% | 387.3B | 50.89 | ₹47.40 | +0.91% |
| WOCKPHARMA.NS | ₹1,881.50 | -3.75% | 309.8B | 75.74 | ₹25.17 | N/A |
| WOCKPHARMA.BO | ₹1,866.20 | -4.26% | 309.8B | 75.74 | ₹25.17 | N/A |
| MEDPLUS.NS | ₹596.90 | -2.46% | 72B | 32.43 | ₹18.48 | N/A |
| MEDPLUS.BO | ₹595.00 | -2.63% | 72B | 31.86 | ₹18.80 | N/A |
| SUPRIYA.NS | ₹847.30 | -4.37% | 70.3B | 33.59 | ₹26.00 | +0.11% |
Stock Comparison
Abbott India Limited (NSE: ABBOTINDIA.NS)
ZENITHDRUG.NS vs ABBOTINDIA.NS Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, ABBOTINDIA.NS has a market cap of 550.5B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while ABBOTINDIA.NS trades at ₹25,725.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas ABBOTINDIA.NS's P/E ratio is 34.98. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to ABBOTINDIA.NS's ROE of +0.38%. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to ABBOTINDIA.NS. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check ABBOTINDIA.NS's competition here
Abbott India Limited (BSE: ABBOTINDIA.BO)
ZENITHDRUG.NS vs ABBOTINDIA.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, ABBOTINDIA.BO has a market cap of 550.5B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while ABBOTINDIA.BO trades at ₹25,698.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas ABBOTINDIA.BO's P/E ratio is 34.89. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to ABBOTINDIA.BO's ROE of +0.38%. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to ABBOTINDIA.BO. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check ABBOTINDIA.BO's competition here
J. B. Chemicals & Pharmaceuticals Limited (NSE: JBCHEPHARM.NS)
ZENITHDRUG.NS vs JBCHEPHARM.NS Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, JBCHEPHARM.NS has a market cap of 387.9B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while JBCHEPHARM.NS trades at ₹2,416.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas JBCHEPHARM.NS's P/E ratio is 52.07. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to JBCHEPHARM.NS's ROE of +0.19%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to JBCHEPHARM.NS. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check JBCHEPHARM.NS's competition here
J. B. Chemicals & Pharmaceuticals Limited (BSE: JBCHEPHARM.BO)
ZENITHDRUG.NS vs JBCHEPHARM.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, JBCHEPHARM.BO has a market cap of 387.3B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while JBCHEPHARM.BO trades at ₹2,412.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas JBCHEPHARM.BO's P/E ratio is 50.89. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to JBCHEPHARM.BO's ROE of +0.19%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to JBCHEPHARM.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check JBCHEPHARM.BO's competition here
Wockhardt Limited (NSE: WOCKPHARMA.NS)
ZENITHDRUG.NS vs WOCKPHARMA.NS Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, WOCKPHARMA.NS has a market cap of 309.8B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while WOCKPHARMA.NS trades at ₹1,881.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas WOCKPHARMA.NS's P/E ratio is 75.74. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to WOCKPHARMA.NS's ROE of +0.08%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to WOCKPHARMA.NS. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check WOCKPHARMA.NS's competition here
Wockhardt Limited (BSE: WOCKPHARMA.BO)
ZENITHDRUG.NS vs WOCKPHARMA.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, WOCKPHARMA.BO has a market cap of 309.8B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while WOCKPHARMA.BO trades at ₹1,866.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas WOCKPHARMA.BO's P/E ratio is 75.74. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to WOCKPHARMA.BO's ROE of +0.08%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to WOCKPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check WOCKPHARMA.BO's competition here
MedPlus Health Services Limited (NSE: MEDPLUS.NS)
ZENITHDRUG.NS vs MEDPLUS.NS Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, MEDPLUS.NS has a market cap of 72B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while MEDPLUS.NS trades at ₹596.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas MEDPLUS.NS's P/E ratio is 32.43. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to MEDPLUS.NS's ROE of +0.11%. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to MEDPLUS.NS. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check MEDPLUS.NS's competition here
MedPlus Health Services Limited (BSE: MEDPLUS.BO)
ZENITHDRUG.NS vs MEDPLUS.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, MEDPLUS.BO has a market cap of 72B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while MEDPLUS.BO trades at ₹595.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas MEDPLUS.BO's P/E ratio is 31.86. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to MEDPLUS.BO's ROE of +0.11%. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to MEDPLUS.BO. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check MEDPLUS.BO's competition here
Supriya Lifescience Limited (NSE: SUPRIYA.NS)
ZENITHDRUG.NS vs SUPRIYA.NS Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, SUPRIYA.NS has a market cap of 70.3B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while SUPRIYA.NS trades at ₹847.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas SUPRIYA.NS's P/E ratio is 33.59. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to SUPRIYA.NS's ROE of +0.17%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to SUPRIYA.NS. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check SUPRIYA.NS's competition here
Supriya Lifescience Limited (BSE: SUPRIYA.BO)
ZENITHDRUG.NS vs SUPRIYA.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, SUPRIYA.BO has a market cap of 70.3B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while SUPRIYA.BO trades at ₹840.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas SUPRIYA.BO's P/E ratio is 35.46. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to SUPRIYA.BO's ROE of +0.17%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to SUPRIYA.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check SUPRIYA.BO's competition here
Sanofi India Limited (NSE: SANOFI.NS)
ZENITHDRUG.NS vs SANOFI.NS Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, SANOFI.NS has a market cap of 66.3B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while SANOFI.NS trades at ₹2,832.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas SANOFI.NS's P/E ratio is 18.97. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to SANOFI.NS's ROE of +0.41%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to SANOFI.NS. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check SANOFI.NS's competition here
Sanofi India Limited (BSE: SANOFI.BO)
ZENITHDRUG.NS vs SANOFI.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, SANOFI.BO has a market cap of 66.3B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while SANOFI.BO trades at ₹2,827.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas SANOFI.BO's P/E ratio is 18.98. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to SANOFI.BO's ROE of +0.41%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to SANOFI.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check SANOFI.BO's competition here
Kwality Pharmaceuticals Limited (BSE: KPL.BO)
ZENITHDRUG.NS vs KPL.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, KPL.BO has a market cap of 34.8B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while KPL.BO trades at ₹3,412.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas KPL.BO's P/E ratio is 42.97. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to KPL.BO's ROE of +0.26%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to KPL.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check KPL.BO's competition here
Shukra Pharmaceuticals Limited (BSE: SHUKRAPHAR.BO)
ZENITHDRUG.NS vs SHUKRAPHAR.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, SHUKRAPHAR.BO has a market cap of 30.2B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while SHUKRAPHAR.BO trades at ₹68.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas SHUKRAPHAR.BO's P/E ratio is 88.61. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to SHUKRAPHAR.BO's ROE of +0.44%. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to SHUKRAPHAR.BO. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check SHUKRAPHAR.BO's competition here
Hikal Limited (NSE: HIKAL.NS)
ZENITHDRUG.NS vs HIKAL.NS Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, HIKAL.NS has a market cap of 26.8B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while HIKAL.NS trades at ₹209.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas HIKAL.NS's P/E ratio is 15.55. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to HIKAL.NS's ROE of -0.03%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to HIKAL.NS. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check HIKAL.NS's competition here
Hikal Limited (BSE: HIKAL.BO)
ZENITHDRUG.NS vs HIKAL.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, HIKAL.BO has a market cap of 26.7B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while HIKAL.BO trades at ₹208.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas HIKAL.BO's P/E ratio is 188.17. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to HIKAL.BO's ROE of -0.03%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to HIKAL.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check HIKAL.BO's competition here
Fredun Pharmaceuticals Limited (BSE: FREDUN.BO)
ZENITHDRUG.NS vs FREDUN.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, FREDUN.BO has a market cap of 23.7B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while FREDUN.BO trades at ₹1,393.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas FREDUN.BO's P/E ratio is 56.28. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to FREDUN.BO's ROE of +0.20%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to FREDUN.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check FREDUN.BO's competition here
Accent Microcell Limited (NSE: ACCENTMIC.NS)
ZENITHDRUG.NS vs ACCENTMIC.NS Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, ACCENTMIC.NS has a market cap of 15.7B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while ACCENTMIC.NS trades at ₹645.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas ACCENTMIC.NS's P/E ratio is 27.59. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to ACCENTMIC.NS's ROE of N/A. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to ACCENTMIC.NS. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check ACCENTMIC.NS's competition here
Vikram Thermo (India) Limited (BSE: VIKRAMTH.BO)
ZENITHDRUG.NS vs VIKRAMTH.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, VIKRAMTH.BO has a market cap of 12B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while VIKRAMTH.BO trades at ₹347.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas VIKRAMTH.BO's P/E ratio is 27.37. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to VIKRAMTH.BO's ROE of +0.30%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to VIKRAMTH.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check VIKRAMTH.BO's competition here
Bharat Parenterals Limited (BSE: BPLPHARMA.BO)
ZENITHDRUG.NS vs BPLPHARMA.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, BPLPHARMA.BO has a market cap of 11.9B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while BPLPHARMA.BO trades at ₹1,779.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas BPLPHARMA.BO's P/E ratio is -77.31. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to BPLPHARMA.BO's ROE of -0.05%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to BPLPHARMA.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check BPLPHARMA.BO's competition here
Remus Pharmaceuticals Ltd. (NSE: REMUS.NS)
ZENITHDRUG.NS vs REMUS.NS Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, REMUS.NS has a market cap of 11.6B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while REMUS.NS trades at ₹930.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas REMUS.NS's P/E ratio is 31.36. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to REMUS.NS's ROE of N/A. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to REMUS.NS. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check REMUS.NS's competition here
Bafna Pharmaceuticals Limited (NSE: BAFNAPH.NS)
ZENITHDRUG.NS vs BAFNAPH.NS Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, BAFNAPH.NS has a market cap of 11.1B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while BAFNAPH.NS trades at ₹472.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas BAFNAPH.NS's P/E ratio is 142.97. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to BAFNAPH.NS's ROE of +0.08%. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to BAFNAPH.NS. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check BAFNAPH.NS's competition here
Bafna Pharmaceuticals Limited (BSE: BAFNAPH.BO)
ZENITHDRUG.NS vs BAFNAPH.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, BAFNAPH.BO has a market cap of 11.1B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while BAFNAPH.BO trades at ₹468.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas BAFNAPH.BO's P/E ratio is 145.20. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to BAFNAPH.BO's ROE of +0.08%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to BAFNAPH.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check BAFNAPH.BO's competition here
Sastasundar Ventures Limited (NSE: SASTASUNDR.NS)
ZENITHDRUG.NS vs SASTASUNDR.NS Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, SASTASUNDR.NS has a market cap of 9B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while SASTASUNDR.NS trades at ₹282.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas SASTASUNDR.NS's P/E ratio is 34.59. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to SASTASUNDR.NS's ROE of -0.03%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to SASTASUNDR.NS. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check SASTASUNDR.NS's competition here
Shree Ganesh Remedies Limited (BSE: SGRL.BO)
ZENITHDRUG.NS vs SGRL.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, SGRL.BO has a market cap of 8.9B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while SGRL.BO trades at ₹645.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas SGRL.BO's P/E ratio is 57.54. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to SGRL.BO's ROE of +0.10%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to SGRL.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check SGRL.BO's competition here
Sudarshan Pharma Industries Ltd. (BSE: SUDARSHAN.BO)
ZENITHDRUG.NS vs SUDARSHAN.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, SUDARSHAN.BO has a market cap of 8.7B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while SUDARSHAN.BO trades at ₹33.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas SUDARSHAN.BO's P/E ratio is 33.04. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to SUDARSHAN.BO's ROE of +0.17%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to SUDARSHAN.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check SUDARSHAN.BO's competition here
One Global Service Provider Ltd. (BSE: ONEGLOBAL.BO)
ZENITHDRUG.NS vs ONEGLOBAL.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, ONEGLOBAL.BO has a market cap of 8.6B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while ONEGLOBAL.BO trades at ₹480.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas ONEGLOBAL.BO's P/E ratio is 11.63. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to ONEGLOBAL.BO's ROE of +0.61%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to ONEGLOBAL.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check ONEGLOBAL.BO's competition here
Albert David Limited (BSE: ALBERTDA.BO)
ZENITHDRUG.NS vs ALBERTDA.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, ALBERTDA.BO has a market cap of 6.2B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while ALBERTDA.BO trades at ₹1,084.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas ALBERTDA.BO's P/E ratio is 32.30. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to ALBERTDA.BO's ROE of +0.06%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to ALBERTDA.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check ALBERTDA.BO's competition here
Praveg Ltd. (BSE: PRAVEG.BO)
ZENITHDRUG.NS vs PRAVEG.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, PRAVEG.BO has a market cap of 5.9B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while PRAVEG.BO trades at ₹214.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas PRAVEG.BO's P/E ratio is -31.17. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to PRAVEG.BO's ROE of -0.04%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to PRAVEG.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check PRAVEG.BO's competition here
Transchem Limited (BSE: TRANSCHEM.BO)
ZENITHDRUG.NS vs TRANSCHEM.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, TRANSCHEM.BO has a market cap of 5.1B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while TRANSCHEM.BO trades at ₹416.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas TRANSCHEM.BO's P/E ratio is 110.54. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to TRANSCHEM.BO's ROE of +0.08%. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to TRANSCHEM.BO. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check TRANSCHEM.BO's competition here
Trident Lifeline Limited (BSE: TLL.BO)
ZENITHDRUG.NS vs TLL.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, TLL.BO has a market cap of 4.8B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while TLL.BO trades at ₹395.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas TLL.BO's P/E ratio is 22.45. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to TLL.BO's ROE of +0.23%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to TLL.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check TLL.BO's competition here
Infinium Pharmachem Ltd. (NSE: INFINIUM.NS)
ZENITHDRUG.NS vs INFINIUM.NS Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, INFINIUM.NS has a market cap of 4.7B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while INFINIUM.NS trades at ₹303.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas INFINIUM.NS's P/E ratio is 38.41. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to INFINIUM.NS's ROE of N/A. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to INFINIUM.NS. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check INFINIUM.NS's competition here
Jenburkt Pharmaceuticals Limited (BSE: JENBURPH.BO)
ZENITHDRUG.NS vs JENBURPH.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, JENBURPH.BO has a market cap of 4.1B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while JENBURPH.BO trades at ₹881.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas JENBURPH.BO's P/E ratio is 12.44. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to JENBURPH.BO's ROE of +0.17%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to JENBURPH.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check JENBURPH.BO's competition here
Ambalal Sarabhai Enterprises Limited (BSE: AMBALALSA.BO)
ZENITHDRUG.NS vs AMBALALSA.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, AMBALALSA.BO has a market cap of 3B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while AMBALALSA.BO trades at ₹37.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas AMBALALSA.BO's P/E ratio is 21.95. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to AMBALALSA.BO's ROE of +0.09%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to AMBALALSA.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check AMBALALSA.BO's competition here
Zenotech Laboratories Limited (BSE: ZENOTECH.BO)
ZENITHDRUG.NS vs ZENOTECH.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, ZENOTECH.BO has a market cap of 2.6B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while ZENOTECH.BO trades at ₹41.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas ZENOTECH.BO's P/E ratio is -104.00. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to ZENOTECH.BO's ROE of -0.03%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to ZENOTECH.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check ZENOTECH.BO's competition here
BDH Industries Limited (BSE: BDH.BO)
ZENITHDRUG.NS vs BDH.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, BDH.BO has a market cap of 2.5B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while BDH.BO trades at ₹455.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas BDH.BO's P/E ratio is 21.73. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to BDH.BO's ROE of +0.16%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to BDH.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check BDH.BO's competition here
Gennex Laboratories Limited (BSE: GENNEX.BO)
ZENITHDRUG.NS vs GENNEX.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, GENNEX.BO has a market cap of 2.2B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while GENNEX.BO trades at ₹8.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas GENNEX.BO's P/E ratio is 11.07. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to GENNEX.BO's ROE of +0.08%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to GENNEX.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check GENNEX.BO's competition here
Sanjivani Paranteral Limited. (BSE: SANJIVIN.BO)
ZENITHDRUG.NS vs SANJIVIN.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, SANJIVIN.BO has a market cap of 2.1B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while SANJIVIN.BO trades at ₹170.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas SANJIVIN.BO's P/E ratio is 28.90. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to SANJIVIN.BO's ROE of +0.16%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to SANJIVIN.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check SANJIVIN.BO's competition here
Kerala Ayurveda Limited (BSE: KERALAYUR.BO)
ZENITHDRUG.NS vs KERALAYUR.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, KERALAYUR.BO has a market cap of 1.9B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while KERALAYUR.BO trades at ₹141.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas KERALAYUR.BO's P/E ratio is -6.91. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to KERALAYUR.BO's ROE of -2.62%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to KERALAYUR.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check KERALAYUR.BO's competition here
Syschem (India) Limited (BSE: SYSCHEM.BO)
ZENITHDRUG.NS vs SYSCHEM.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, SYSCHEM.BO has a market cap of 1.9B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while SYSCHEM.BO trades at ₹35.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas SYSCHEM.BO's P/E ratio is 585.33. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to SYSCHEM.BO's ROE of +0.06%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to SYSCHEM.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check SYSCHEM.BO's competition here
Coral Laboratories Limited (BSE: CORALAB.BO)
ZENITHDRUG.NS vs CORALAB.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, CORALAB.BO has a market cap of 1.9B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while CORALAB.BO trades at ₹515.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas CORALAB.BO's P/E ratio is 9.76. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to CORALAB.BO's ROE of +0.09%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to CORALAB.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check CORALAB.BO's competition here
Oxygenta Pharmaceutical Ltd. (BSE: OXYGENTAPH.BO)
ZENITHDRUG.NS vs OXYGENTAPH.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, OXYGENTAPH.BO has a market cap of 1.7B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while OXYGENTAPH.BO trades at ₹46.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas OXYGENTAPH.BO's P/E ratio is -12.69. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to OXYGENTAPH.BO's ROE of +0.34%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to OXYGENTAPH.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check OXYGENTAPH.BO's competition here
Smruthi Organics Limited (BSE: SMRUTHIORG.BO)
ZENITHDRUG.NS vs SMRUTHIORG.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, SMRUTHIORG.BO has a market cap of 1.6B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while SMRUTHIORG.BO trades at ₹137.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas SMRUTHIORG.BO's P/E ratio is 21.75. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to SMRUTHIORG.BO's ROE of +0.10%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to SMRUTHIORG.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check SMRUTHIORG.BO's competition here
Quest Laboratories Ltd. (NSE: QUESTLAB.NS)
ZENITHDRUG.NS vs QUESTLAB.NS Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, QUESTLAB.NS has a market cap of 1.5B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while QUESTLAB.NS trades at ₹90.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas QUESTLAB.NS's P/E ratio is 9.84. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to QUESTLAB.NS's ROE of N/A. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to QUESTLAB.NS. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check QUESTLAB.NS's competition here
Kimia Biosciences Ltd. (BSE: KIMIABL.BO)
ZENITHDRUG.NS vs KIMIABL.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, KIMIABL.BO has a market cap of 1.5B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while KIMIABL.BO trades at ₹31.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas KIMIABL.BO's P/E ratio is 20.41. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to KIMIABL.BO's ROE of +0.49%. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to KIMIABL.BO. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check KIMIABL.BO's competition here
Auro Laboratories Limited (BSE: AUROLAB.BO)
ZENITHDRUG.NS vs AUROLAB.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, AUROLAB.BO has a market cap of 1.4B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while AUROLAB.BO trades at ₹228.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas AUROLAB.BO's P/E ratio is 30.80. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to AUROLAB.BO's ROE of +0.10%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to AUROLAB.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check AUROLAB.BO's competition here
Panchsheel Organics Limited (BSE: PANCHSHEEL.BO)
ZENITHDRUG.NS vs PANCHSHEEL.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, PANCHSHEEL.BO has a market cap of 1.4B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while PANCHSHEEL.BO trades at ₹102.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas PANCHSHEEL.BO's P/E ratio is 12.65. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to PANCHSHEEL.BO's ROE of +0.07%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to PANCHSHEEL.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check PANCHSHEEL.BO's competition here
Lactose (India) Limited (BSE: LACTOSE.BO)
ZENITHDRUG.NS vs LACTOSE.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, LACTOSE.BO has a market cap of 1.3B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while LACTOSE.BO trades at ₹103.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas LACTOSE.BO's P/E ratio is 18.40. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to LACTOSE.BO's ROE of +0.11%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to LACTOSE.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check LACTOSE.BO's competition here
Godavari Drugs Limited (BSE: GODAVARI.BO)
ZENITHDRUG.NS vs GODAVARI.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, GODAVARI.BO has a market cap of 1.3B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while GODAVARI.BO trades at ₹119.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas GODAVARI.BO's P/E ratio is 28.41. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to GODAVARI.BO's ROE of +0.07%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to GODAVARI.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check GODAVARI.BO's competition here
Parnax Lab Limited (BSE: PARNAXLAB.BO)
ZENITHDRUG.NS vs PARNAXLAB.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, PARNAXLAB.BO has a market cap of 1.2B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while PARNAXLAB.BO trades at ₹108.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas PARNAXLAB.BO's P/E ratio is 13.94. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to PARNAXLAB.BO's ROE of +0.10%. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to PARNAXLAB.BO. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check PARNAXLAB.BO's competition here
Makers Laboratories Limited (BSE: MAKERSL.BO)
ZENITHDRUG.NS vs MAKERSL.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, MAKERSL.BO has a market cap of 1.2B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while MAKERSL.BO trades at ₹200.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas MAKERSL.BO's P/E ratio is 35.47. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to MAKERSL.BO's ROE of +0.04%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to MAKERSL.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check MAKERSL.BO's competition here
Pharmaids Pharmaceuticals Limited (BSE: PHARMAID.BO)
ZENITHDRUG.NS vs PHARMAID.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, PHARMAID.BO has a market cap of 1.1B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while PHARMAID.BO trades at ₹29.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas PHARMAID.BO's P/E ratio is -24.17. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to PHARMAID.BO's ROE of -0.09%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to PHARMAID.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check PHARMAID.BO's competition here
Tyche Industries Limited (BSE: TYCHE.BO)
ZENITHDRUG.NS vs TYCHE.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, TYCHE.BO has a market cap of 1.1B. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while TYCHE.BO trades at ₹103.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas TYCHE.BO's P/E ratio is 23.68. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to TYCHE.BO's ROE of +0.03%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to TYCHE.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check TYCHE.BO's competition here
Sotac Pharmaceuticals Ltd. (NSE: SOTAC.NS)
ZENITHDRUG.NS vs SOTAC.NS Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, SOTAC.NS has a market cap of 995.1M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while SOTAC.NS trades at ₹92.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas SOTAC.NS's P/E ratio is 17.24. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to SOTAC.NS's ROE of N/A. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to SOTAC.NS. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check SOTAC.NS's competition here
Mercury Laboratories Limited (BSE: MERCURYLAB.BO)
ZENITHDRUG.NS vs MERCURYLAB.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, MERCURYLAB.BO has a market cap of 894.8M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while MERCURYLAB.BO trades at ₹740.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas MERCURYLAB.BO's P/E ratio is 21.49. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to MERCURYLAB.BO's ROE of +0.07%. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to MERCURYLAB.BO. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check MERCURYLAB.BO's competition here
Denis Chem Lab Limited (BSE: DENISCHEM.BO)
ZENITHDRUG.NS vs DENISCHEM.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, DENISCHEM.BO has a market cap of 869.2M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while DENISCHEM.BO trades at ₹62.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas DENISCHEM.BO's P/E ratio is 10.89. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to DENISCHEM.BO's ROE of +0.09%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to DENISCHEM.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check DENISCHEM.BO's competition here
Vaishali Pharma Limited (NSE: VAISHALI.NS)
ZENITHDRUG.NS vs VAISHALI.NS Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, VAISHALI.NS has a market cap of 803.9M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while VAISHALI.NS trades at ₹7.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas VAISHALI.NS's P/E ratio is 23.36. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to VAISHALI.NS's ROE of +0.06%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to VAISHALI.NS. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check VAISHALI.NS's competition here
Concord Drugs Limited (BSE: CONCORD.BO)
ZENITHDRUG.NS vs CONCORD.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, CONCORD.BO has a market cap of 755.2M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while CONCORD.BO trades at ₹66.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas CONCORD.BO's P/E ratio is 40.48. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to CONCORD.BO's ROE of +0.05%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to CONCORD.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check CONCORD.BO's competition here
Vilin Bio Med Ltd. (NSE: VILINBIO.NS)
ZENITHDRUG.NS vs VILINBIO.NS Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, VILINBIO.NS has a market cap of 742.8M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while VILINBIO.NS trades at ₹51.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas VILINBIO.NS's P/E ratio is 41.79. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to VILINBIO.NS's ROE of N/A. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to VILINBIO.NS. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check VILINBIO.NS's competition here
Sunil Healthcare Ltd. (BSE: SUNLOC.BO)
ZENITHDRUG.NS vs SUNLOC.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, SUNLOC.BO has a market cap of 717.8M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while SUNLOC.BO trades at ₹70.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas SUNLOC.BO's P/E ratio is 20.16. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to SUNLOC.BO's ROE of +0.05%. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to SUNLOC.BO. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check SUNLOC.BO's competition here
Source Natural Foods & Herbal Supplements Ltd. (BSE: SOURCENTRL.BO)
ZENITHDRUG.NS vs SOURCENTRL.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, SOURCENTRL.BO has a market cap of 701.6M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while SOURCENTRL.BO trades at ₹107.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas SOURCENTRL.BO's P/E ratio is 20.64. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to SOURCENTRL.BO's ROE of +0.14%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to SOURCENTRL.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check SOURCENTRL.BO's competition here
Phaarmasia Limited (BSE: PHRMASI.BO)
ZENITHDRUG.NS vs PHRMASI.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, PHRMASI.BO has a market cap of 546.2M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while PHRMASI.BO trades at ₹80.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas PHRMASI.BO's P/E ratio is 3.11. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to PHRMASI.BO's ROE of +1.07%. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to PHRMASI.BO. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check PHRMASI.BO's competition here
Shelter Pharma Limited (BSE: SHELTER.BO)
ZENITHDRUG.NS vs SHELTER.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, SHELTER.BO has a market cap of 544.9M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while SHELTER.BO trades at ₹47.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas SHELTER.BO's P/E ratio is 8.72. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to SHELTER.BO's ROE of +0.13%. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to SHELTER.BO. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check SHELTER.BO's competition here
Parmax Pharma Limited (BSE: PARMAX.BO)
ZENITHDRUG.NS vs PARMAX.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, PARMAX.BO has a market cap of 510.3M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while PARMAX.BO trades at ₹136.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas PARMAX.BO's P/E ratio is -44.29. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to PARMAX.BO's ROE of +0.22%. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to PARMAX.BO. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check PARMAX.BO's competition here
ANG Lifesciences India Limited (BSE: ANG.BO)
ZENITHDRUG.NS vs ANG.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, ANG.BO has a market cap of 493M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while ANG.BO trades at ₹37.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas ANG.BO's P/E ratio is -3.70. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to ANG.BO's ROE of -0.23%. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to ANG.BO. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check ANG.BO's competition here
Vasundhara Rasayans Limited (BSE: VRL.BO)
ZENITHDRUG.NS vs VRL.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, VRL.BO has a market cap of 432.4M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while VRL.BO trades at ₹133.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas VRL.BO's P/E ratio is 7.46. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to VRL.BO's ROE of +0.15%. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to VRL.BO. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check VRL.BO's competition here
Bharat Immunologicals & Biologicals Corporation Limited (BSE: BIBCL.BO)
ZENITHDRUG.NS vs BIBCL.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, BIBCL.BO has a market cap of 412.4M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while BIBCL.BO trades at ₹9.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas BIBCL.BO's P/E ratio is -3.77. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to BIBCL.BO's ROE of -0.17%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to BIBCL.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check BIBCL.BO's competition here
Medicamen Organics Ltd (NSE: MEDIORG.NS)
ZENITHDRUG.NS vs MEDIORG.NS Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, MEDIORG.NS has a market cap of 398M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while MEDIORG.NS trades at ₹25.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas MEDIORG.NS's P/E ratio is -7.84. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to MEDIORG.NS's ROE of N/A. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to MEDIORG.NS. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check MEDIORG.NS's competition here
Vista Pharmaceuticals Limited (BSE: VISTAPH.BO)
ZENITHDRUG.NS vs VISTAPH.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, VISTAPH.BO has a market cap of 376.1M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while VISTAPH.BO trades at ₹5.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas VISTAPH.BO's P/E ratio is -3.17. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to VISTAPH.BO's ROE of -0.27%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to VISTAPH.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check VISTAPH.BO's competition here
Panjon Ltd. (BSE: PANJON.BO)
ZENITHDRUG.NS vs PANJON.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, PANJON.BO has a market cap of 350.2M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while PANJON.BO trades at ₹19.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas PANJON.BO's P/E ratio is 127.50. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to PANJON.BO's ROE of +0.04%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to PANJON.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check PANJON.BO's competition here
Roopa Industries Limited (BSE: ROOPAIND.BO)
ZENITHDRUG.NS vs ROOPAIND.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, ROOPAIND.BO has a market cap of 341.3M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while ROOPAIND.BO trades at ₹43.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas ROOPAIND.BO's P/E ratio is 333.77. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to ROOPAIND.BO's ROE of +0.01%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to ROOPAIND.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check ROOPAIND.BO's competition here
Sandu Pharmaceuticals Limited (BSE: SANDUPHQ.BO)
ZENITHDRUG.NS vs SANDUPHQ.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, SANDUPHQ.BO has a market cap of 339.4M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while SANDUPHQ.BO trades at ₹35.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas SANDUPHQ.BO's P/E ratio is 19.30. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to SANDUPHQ.BO's ROE of +0.04%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to SANDUPHQ.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check SANDUPHQ.BO's competition here
Medi-Caps Limited (BSE: MEDICAPQ.BO)
ZENITHDRUG.NS vs MEDICAPQ.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, MEDICAPQ.BO has a market cap of 320.5M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while MEDICAPQ.BO trades at ₹25.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas MEDICAPQ.BO's P/E ratio is -18.02. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to MEDICAPQ.BO's ROE of -0.02%. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to MEDICAPQ.BO. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check MEDICAPQ.BO's competition here
Deccan Health Care Ltd (BSE: DECCAN.BO)
ZENITHDRUG.NS vs DECCAN.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, DECCAN.BO has a market cap of 315.3M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while DECCAN.BO trades at ₹12.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas DECCAN.BO's P/E ratio is 12.49. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to DECCAN.BO's ROE of +0.02%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to DECCAN.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check DECCAN.BO's competition here
Bacil Pharma Limited (BSE: BACPHAR.BO)
ZENITHDRUG.NS vs BACPHAR.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, BACPHAR.BO has a market cap of 291.9M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while BACPHAR.BO trades at ₹20.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas BACPHAR.BO's P/E ratio is 68.12. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to BACPHAR.BO's ROE of +0.02%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to BACPHAR.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check BACPHAR.BO's competition here
Gujarat Terce Laboratories Limited (BSE: GUJTERC.BO)
ZENITHDRUG.NS vs GUJTERC.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, GUJTERC.BO has a market cap of 273.1M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while GUJTERC.BO trades at ₹34.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas GUJTERC.BO's P/E ratio is 12.66. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to GUJTERC.BO's ROE of +0.24%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to GUJTERC.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check GUJTERC.BO's competition here
Trimurthi Limited (BSE: TRIMURTHI.BO)
ZENITHDRUG.NS vs TRIMURTHI.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, TRIMURTHI.BO has a market cap of 264.8M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while TRIMURTHI.BO trades at ₹26.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas TRIMURTHI.BO's P/E ratio is 102.35. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to TRIMURTHI.BO's ROE of +0.10%. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to TRIMURTHI.BO. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check TRIMURTHI.BO's competition here
Welcure Drugs & Pharmaceuticals Limited (BSE: WELCURE.BO)
ZENITHDRUG.NS vs WELCURE.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, WELCURE.BO has a market cap of 234.8M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while WELCURE.BO trades at ₹0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas WELCURE.BO's P/E ratio is -9.44. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to WELCURE.BO's ROE of -0.34%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to WELCURE.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check WELCURE.BO's competition here
Ishita Drugs and Industries Limited (BSE: ISHITADR.BO)
ZENITHDRUG.NS vs ISHITADR.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, ISHITADR.BO has a market cap of 232.6M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while ISHITADR.BO trades at ₹77.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas ISHITADR.BO's P/E ratio is 32.93. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to ISHITADR.BO's ROE of +0.06%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to ISHITADR.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check ISHITADR.BO's competition here
Chemo Pharma Laboratories Limited (BSE: CHEMOPH.BO)
ZENITHDRUG.NS vs CHEMOPH.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, CHEMOPH.BO has a market cap of 196.3M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while CHEMOPH.BO trades at ₹130.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas CHEMOPH.BO's P/E ratio is -1.61. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to CHEMOPH.BO's ROE of +0.03%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to CHEMOPH.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check CHEMOPH.BO's competition here
Zenlabs Ethica Limited (BSE: ZENLABS.BO)
ZENITHDRUG.NS vs ZENLABS.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, ZENLABS.BO has a market cap of 178.1M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while ZENLABS.BO trades at ₹27.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas ZENLABS.BO's P/E ratio is -7.30. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to ZENLABS.BO's ROE of -0.27%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to ZENLABS.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check ZENLABS.BO's competition here
Colinz Laboratories Limited (BSE: COLINZ.BO)
ZENITHDRUG.NS vs COLINZ.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, COLINZ.BO has a market cap of 176.3M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while COLINZ.BO trades at ₹69.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas COLINZ.BO's P/E ratio is 6.31. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to COLINZ.BO's ROE of +0.28%. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to COLINZ.BO. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check COLINZ.BO's competition here
Sunrest Lifescience Ltd. (NSE: SUNREST.NS)
ZENITHDRUG.NS vs SUNREST.NS Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, SUNREST.NS has a market cap of 161.6M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while SUNREST.NS trades at ₹35.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas SUNREST.NS's P/E ratio is 4.34. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to SUNREST.NS's ROE of N/A. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to SUNREST.NS. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check SUNREST.NS's competition here
Norris Medicines Limited (BSE: NORRIS.BO)
ZENITHDRUG.NS vs NORRIS.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, NORRIS.BO has a market cap of 160M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while NORRIS.BO trades at ₹15.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas NORRIS.BO's P/E ratio is N/A. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to NORRIS.BO's ROE of +0.02%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to NORRIS.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check NORRIS.BO's competition here
Shamrock Industrial Co. Ltd. (BSE: SHAMROIN.BO)
ZENITHDRUG.NS vs SHAMROIN.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, SHAMROIN.BO has a market cap of 147.9M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while SHAMROIN.BO trades at ₹27.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas SHAMROIN.BO's P/E ratio is -13.79. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to SHAMROIN.BO's ROE of -1.27%. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to SHAMROIN.BO. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check SHAMROIN.BO's competition here
Beryl Drugs Limited (BSE: BERLDRG.BO)
ZENITHDRUG.NS vs BERLDRG.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, BERLDRG.BO has a market cap of 126M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while BERLDRG.BO trades at ₹24.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas BERLDRG.BO's P/E ratio is 20.17. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to BERLDRG.BO's ROE of +0.07%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to BERLDRG.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check BERLDRG.BO's competition here
Emmessar Biotech & Nutrition Limited (BSE: EMMESSA.BO)
ZENITHDRUG.NS vs EMMESSA.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, EMMESSA.BO has a market cap of 106.6M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while EMMESSA.BO trades at ₹24.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas EMMESSA.BO's P/E ratio is 26.33. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to EMMESSA.BO's ROE of +0.05%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to EMMESSA.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check EMMESSA.BO's competition here
Kobo Biotech Ltd. (BSE: KOBO.BO)
ZENITHDRUG.NS vs KOBO.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, KOBO.BO has a market cap of 101.7M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while KOBO.BO trades at ₹4.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas KOBO.BO's P/E ratio is -1.56. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to KOBO.BO's ROE of +0.04%. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to KOBO.BO. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check KOBO.BO's competition here
Adline Chem Lab Ltd. (BSE: ADLINE.BO)
ZENITHDRUG.NS vs ADLINE.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, ADLINE.BO has a market cap of 92.4M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while ADLINE.BO trades at ₹15.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas ADLINE.BO's P/E ratio is N/A. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to ADLINE.BO's ROE of N/A. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to ADLINE.BO. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check ADLINE.BO's competition here
Ganga Pharmaceuticals Limited (BSE: GANGAPHARM.BO)
ZENITHDRUG.NS vs GANGAPHARM.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, GANGAPHARM.BO has a market cap of 73.9M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while GANGAPHARM.BO trades at ₹12.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas GANGAPHARM.BO's P/E ratio is 73.53. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to GANGAPHARM.BO's ROE of +0.01%. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to GANGAPHARM.BO. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check GANGAPHARM.BO's competition here
Trinity League India Limited (BSE: TRINITYLEA.BO)
ZENITHDRUG.NS vs TRINITYLEA.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, TRINITYLEA.BO has a market cap of 73.7M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while TRINITYLEA.BO trades at ₹9.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas TRINITYLEA.BO's P/E ratio is -54.76. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to TRINITYLEA.BO's ROE of -0.05%. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to TRINITYLEA.BO. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check TRINITYLEA.BO's competition here
Hindustan Bio Sciences Limited (BSE: HINDBIO.BO)
ZENITHDRUG.NS vs HINDBIO.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, HINDBIO.BO has a market cap of 71.3M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while HINDBIO.BO trades at ₹6.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas HINDBIO.BO's P/E ratio is -34.63. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to HINDBIO.BO's ROE of -0.24%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to HINDBIO.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check HINDBIO.BO's competition here
Vivanza Biosciences Limited (BSE: VIVANZA.BO)
ZENITHDRUG.NS vs VIVANZA.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, VIVANZA.BO has a market cap of 67.6M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while VIVANZA.BO trades at ₹1.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas VIVANZA.BO's P/E ratio is 14.88. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to VIVANZA.BO's ROE of +0.10%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to VIVANZA.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check VIVANZA.BO's competition here
Tiaan Consumer Ltd. (BSE: TIAANC.BO)
ZENITHDRUG.NS vs TIAANC.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, TIAANC.BO has a market cap of 64.5M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while TIAANC.BO trades at ₹6.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas TIAANC.BO's P/E ratio is -48.31. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to TIAANC.BO's ROE of -0.01%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to TIAANC.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check TIAANC.BO's competition here
Decipher Labs Ltd. (BSE: DECIPHER.BO)
ZENITHDRUG.NS vs DECIPHER.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, DECIPHER.BO has a market cap of 55.6M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while DECIPHER.BO trades at ₹5.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas DECIPHER.BO's P/E ratio is -1.82. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to DECIPHER.BO's ROE of -0.09%. Regarding short-term risk, ZENITHDRUG.NS is less volatile compared to DECIPHER.BO. This indicates lower risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check DECIPHER.BO's competition here
TMT (India) Ltd. (BSE: TMTIND-B1.BO)
ZENITHDRUG.NS vs TMTIND-B1.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, TMTIND-B1.BO has a market cap of 43.9M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while TMTIND-B1.BO trades at ₹8.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas TMTIND-B1.BO's P/E ratio is -177.40. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to TMTIND-B1.BO's ROE of N/A. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to TMTIND-B1.BO. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check TMTIND-B1.BO's competition here
Fabino Enterprises Ltd (BSE: FABINO.BO)
ZENITHDRUG.NS vs FABINO.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, FABINO.BO has a market cap of 42.7M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while FABINO.BO trades at ₹20.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas FABINO.BO's P/E ratio is -7.64. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to FABINO.BO's ROE of +0.01%. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to FABINO.BO. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check FABINO.BO's competition here
Patidar Buildcon Limited (BSE: PATIDAR.BO)
ZENITHDRUG.NS vs PATIDAR.BO Comparison October 2026
Zenith Drugs Ltd. (NSE: ZENITHDRUG.NS) plays a significant role within the Healthcare sector. Its performance on the NSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ZENITHDRUG.NS stands at 668.8M. In comparison, PATIDAR.BO has a market cap of 35.6M. Regarding current trading prices, ZENITHDRUG.NS is priced at ₹39.80 on the NSE, while PATIDAR.BO trades at ₹6.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ZENITHDRUG.NS currently has a P/E ratio of 16.96, whereas PATIDAR.BO's P/E ratio is -15.43. In terms of profitability, ZENITHDRUG.NS's ROE is N/A, compared to PATIDAR.BO's ROE of -0.03%. Regarding short-term risk, ZENITHDRUG.NS is more volatile compared to PATIDAR.BO. This indicates higher risk in terms of short-term price fluctuations for ZENITHDRUG.NS.Check PATIDAR.BO's competition here